Latest News and Press Releases

- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of first-generation,...

– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor reduction) and durable (11 months) partial response and two longstanding (8 and 10...

- ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head...

BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a  clinical-stage immunotherapy company focused on the discovery and development of next...

BOSTON and ROCKVILLE, Md., April 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next...

 -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in...

BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next...

BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation...

BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation...

BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation...